September 1, 1998Nephrology Dialysis Transplantation

Fosinopril ameliorates exogenous cholesterol-induced incipient glomerular lesions in obese Zucker rats. Effects on eicosanoid secretion

View Full Paper

Ask AI

Bookmark

Why the study?

Does fosinopril reduce exogenous cholesterol-induced glomerular lesions and eicosanoid secretion in obese Zucker rats?

Population

Obese Zucker rats (OZRs) as a model of early nephropathy

Design

Preclinical

Authors

SHS HIGUERUELOUniversitat Autònoma de Barcelona

Discussion

Member takes

Implication

Hypothesis-generating for ACE inhibition in hypercholesterolemic nephropathy; leaves open clinical translation in obese CKD patients.

Structured PICO

Does fosinopril reduce exogenous cholesterol-induced glomerular lesions and eicosanoid secretion in obese Zucker rats?

Population

Obese Zucker rats (OZRs) as a model of early nephropathy

Intervention

Fosinopril (evaluated both in vivo and in vitro using 24 h glomeruli cultures)

Outcome

Glomerular eicosanoid secretion, serum cholesterol, proteinuria, and development of glomerular lesionssurrogate

Fosinopril ameliorates cholesterol-induced early nephropathy markers and glomerular lesions in an obese Zucker rat model, likely by modulating angiotensin II and eicosanoid pathways.

Cite This Study

S HIGUERUELO (1998) studied this question.

synapsesocial.com/papers/6a9088f87b6e700e2c8a6021 https://doi.org/10.1093/ndt/13.9.2227

View Full Paper

Ask AI

Bookmark

Fosinopril ameliorates exogenous cholesterol-induced incipient glomerular lesions in obese Zucker rats. Effects on eicosanoid secretion

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Fosinopril ameliorates exogenous cholesterol-induced incipient glomerular lesions in obese Zucker rats. Effects on eicosanoid secretion

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider